Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Top Read Articles

    Published in last 1 year |  In last 2 years |  In last 3 years |  All
    Please wait a minute...
    For Selected: Toggle Thumbnails
    A novel antibody-drug conjugate: disitamab vedotin
    YIN Xiaoyu, LU Ming, YU Zefang, PANG Guoxun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (11): 1315-1320.   DOI: 10.12092/j.issn.1009-2501.2024.11.015
    Abstract1344)      PDF (673KB)(846)       Save
    Antibody drug conjugates (ADCs) are a new class of anti-tumor drugs in which linkers in the structure link cytotoxic drugs to monoclonal antibodies and release cytotoxic drugs to tumors. Disitamab vedotin (RC48) is a new antibody-drug conjugate independently developed in China. It targets the HER2 protein on the surface of tumors, it has both antibody targeting and small molecule drug killing, and can accurately recognize and kill tumor cells. Compared with traditional HER2-targeted drugs, disitamab vedotin has a wider therapeutic window and less toxicity to normal tissues. Currently, disitamab vedotin for injection has been approved by the National Medical Products Administration (NMPA) for use in patients with HER2 overexpression (HER2 immunohistochemical results of 2+ or 3+) who have locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) and have received at least two types of systemic chemotherapy. Additionally, it is indicated for patients with locally advanced or metastatic urothelial carcinoma who have previously undergone platinum-containing chemotherapy and exhibit HER2 overexpression, specifically 2+ or 3+ immunohistochemical results. In this paper, we will review the structural characteristics, mechanism of action and clinical trials of disitamab vedotin and look forward to the clinical application prospects of this drug.
    Related Articles | Metrics
    Pharmacological effects and clinical evaluation of toludesvenlafaxine in the treatment of depression
    LI Yumeng, DU Xiaoyu, QIU bo, WU Huizhen
    Chinese Journal of Clinical Pharmacology and Therapeutics    2025, 30 (3): 419-426.   DOI: 10.12092/j.issn.1009-2501.2025.03.016
    Abstract1293)      PDF (954KB)(780)       Save
    Depression is a common mental disease. At present, there are poor efficacy and drug-related safety problems in antidepressant treatment. Toludesvenlafaxine, as a new triple reuptake inhibitor (TRIs/SNDRIs), increases the inhibitory effect of dopamine (DA) reuptake on the basis of serotonin (5-HT) and norepinephrine (NE), achieves multi-target synergistic therapy and reduces 5-HT/NE-related adverse drug reactions. This article reviews the basic introduction, preclinical research, clinical efficacy and safety of toludesvenlafaxine, in order to provide more ideas and options for the treatment of depression.
    Related Articles | Metrics
    Advancements and frontiers in targeted therapy for pancreatic cancer
    DU Nan, WEI Miaoyan, XU Jin
    Chinese Journal of Clinical Pharmacology and Therapeutics    2025, 30 (2): 183-192.   DOI: 10.12092/j.issn.1009-2501.2025.02.004
    Abstract1161)      PDF (762KB)(1868)       Save
    The incidence of pancreatic cancer has been increasing each year, and the 5-year survival rate is still around 10%. Diagnosis and treatment strategies are major concerns in the industry. Gene sequencing and multi-omics research have revealed more signal pathways and actionable targets, offering the potential for new targeted therapeutic drugs. However, current drug treatment for pancreatic cancer still relies mainly on chemotherapy, and targeted therapy strategies are not yet fully developed and require further discussion. As basic and translational research in pancreatic cancer advances and precision medicine develops, it is expected that targeted treatment for pancreatic cancer will become more precise and individualized in the future. This article discusses the current progress and frontiers of targeted treatment for pancreatic cancer.
    Related Articles | Metrics
    Comparison of clinical effectiveness and safety between generic and branded dienogest tablets in the treatment of endometriosis
    LIU Qian, ZHANG Jianing, ZHANG Shuang, LIU Qinglan, ZHANG Baoyin, SUN Nan
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (5): 527-534.   DOI: 10.12092/j.issn.1009-2501.2024.05.007
    Abstract1157)      PDF (1781KB)(455)       Save
    AIM: To evaluate the clinical effectiveness and safety of generic and branded dienogest in the treatment of endometriosis. so as to provide the basis for clinical use of dienogest. MEHTODS: The data of patients admitted to Third Affiliated Hospital of Zhengzhou University from August 2022 to August 2023 who received dienogest (2 mg/d, orally, for 6 months) for treatment of endometriosis were collected. The clinical efficacy and adverse reactions of generic drugs and original drugs in the treatment of endometriosis-related pain were compared through follow-up surveys of the two groups of patients at 3 months and 6 months respectively. RESULTS: There was highly significant reduction in pelvic pain in both groups with mean of similar in generic group (34.0±3.0) mm and branded group (34.5±3.9) mm. The most frequent drug-related adverse effects in generic dienogest was vaginal bleeding (93%) which was no statistical difference with branded dienogest (90%). CONCLUSION: The generic and branded dienogest have the same clinical effectiveness and similar safety.
    Related Articles | Metrics
    Progress in the clinical application of the biased μ-opioid agonist oliceridine
    ZHU Changmao, XIE Li, WU Zifeng, WANG Sen, ZHANG Qi, XU Xiangqing, YANG Chun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (9): 1057-1061.   DOI: 10.12092/j.issn.1009-2501.2024.09.012
    Abstract1096)      PDF (596KB)(1481)       Save
    Opioid receptors μOR, δOR, κOR and NOPR are all G protein-coupled receptors (GPCRs), which mainly function through G protein and β-arrestin. Recent studies have found that G protein mediates analgesia, while β-arrestin reduces analgesia and is related to the side effects of opioids. Oliceridine is the first biased μOR agonist approved for commerce. It mainly exerts analgesic effect by activating G protein. It has rapid onset of action and reliable analgesic effect. Due to its low activity on β-arrestin, the incidence of side effects is low, comparing to the classic opioid morphine. Oliceridine can be safely used in patients with liver or kidney insufficiency and its metabolite is inactive. This article summarizes the current progress of pharmacological research and clinical application of oliceridine, aiming to provide reference for the clinical practice of oliceridine.
    Related Articles | Metrics
    Expert consensus on the diagnosis and treatment of insomnia in specified populations
    CHEN Guihai, DENG Liying, DU Yijie, HUANG Zhili, JIANG Fan, JIN Furui, LI Yanpeng, LIU Chunfeng, PAN Jiyang, PENG Yanhui, SU Changjun, TANG Jiyou, WANG Tao, WANG Zan, WU Huijuan, XUE Rong, YANG Yuechang, YU Fengchun, YU Huan, ZHAN Shuqin, ZHANG Hongju, ZHANG Lin, ZHAO Zhengqing, ZHAO Zhongxin
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (8): 841-852.   DOI: 10.12092/j.issn.1009-2501.2024.08.001
    Abstract1075)      PDF (795KB)(1561)       Save
    Clinicians need to focus on various points in the diagnosis and treatment of insomnia. This article prescribed the treatment protocol based on the unique features, such as insomnia in the elderly, women experiencing specific physiological periods, children insomnia, insomnia in sleep-breathing disorder patients, insomnia in patients with chronic liver and kidney dysfunction. It provides some reference for clinicians while they make decision on diagnosis, differentiation and treatment methods.
    Related Articles | Metrics
    Research progress on targeted therapy combined with immune-activating strategies in CLDN18.2-positive gastric cancer
    NIE Yang, WANG Yue, WEI Jia
    Chinese Journal of Clinical Pharmacology and Therapeutics    2025, 30 (2): 146-158.   DOI: 10.12092/j.issn.1009-2501.2025.02.001
    Abstract1069)      PDF (1213KB)(1740)       Save
    Claudin 18 isoform 2 (Claudin18.2, CLDN18.2) is a crucial structural protein involved in cell-cell tight junctions. While its expression is limited in normal tissues, it is specifically overexpressed in malignant tumors such as gastric cancer, pancreatic cancer, and esophageal cancer, making it a promising therapeutic target for cancer treatment. Recent advances in CLDN18.2-targeted therapies have been encouraging, and studies suggest that CLDN18.2-positive gastric cancer may possess a unique immune microenvironment. This raises the potential for combining targeted therapies with immune activation to achieve synergistic effects, potentially improving treatment outcomes for patients with advanced gastric cancer. This review will focus on the immune microenvironment characteristics of CLDN18.2-positive gastric cancer and summarize the current research and clinical trial progress in targeted therapies combined with immune activation for this specific cancer type.
    Related Articles | Metrics
    Research progress in the treatment of early Alzheimer's disease with lecanemab
    JIN Panpan, LIU Yang, QIU Bo, WU Huizhen
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (2): 207-214.   DOI: 10.12092/j.issn.1009-2501.2024.02.011
    Abstract1068)      PDF (672KB)(1554)       Save
    Lecanemab is a new drug used to treat early Alzheimer's disease (AD) with mild cognitive impairment or mild dementia. It is a human anti-Aβ fibril monoclonal IgG1 antibody, which is injected intravenously into the patient, through the blood-brain barrier into the brain, clearing amyloid plaque, thereby slowing the rate of cognitive decline in patients and delaying disease progression. This article reviews the pharmacological studies, clinical studies, safety and limitations of lecanemab, in order to help clinical understand the current research status and existing achievements of this drug.
    Related Articles | Metrics
    Mechanism of action and research progress of vaccine adjuvants
    ZHANG Li, LU Chang, AN Minghui, WANG Mengmeng, ZONG Xiaoyu, YU Lin, RAN Zhuo-ling, SONG Jing, LI Huijie, GONG Jian
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (7): 785-791.   DOI: 10.12092/j.issn.1009-2501.2024.07.008
    Abstract1003)      PDF (831KB)(2747)       Save
    Vaccines are among the most effective measures for preventing infectious diseases and play a crucial role in controlling the spread of these diseases. Adjuvants, serving as auxiliary components in vaccines, are indispensable in the vaccine development process. Ideal adjuvants not only enhance the immune response, enabling the body to achieve optimal protective immunity but also play important roles in reducing the dosage of immunogens and lowering vaccine production costs. To meet the demands of novel vaccines, many new types of adjuvants have been developed. However, there is still a lack of adjuvants that are safe, effective, easy to prepare, highly pure, and suitable for a variety of vaccines in clinical settings. This article categorizes adjuvants and summarizes their mechanisms of action and characteristics, focusing on traditional aluminum salt adjuvants and more modern lipid-based and nucleic acid-based adjuvants. The summary is based on a computer search of databases including PubMed, Embase, The Cochrane Library, CNKI (China National Knowledge Infrastructure), VIP Database, and Wanfang Database, using English search keywords such as Adjuvants, Vaccine, Vaccine Adjuvant, aluminum salts, MF59, AS03, Toll-like receptor agonist, etc., and corresponding Chinese search terms. The aim is to provide references for the development and application of adjuvants.
    Related Articles | Metrics
    Progress and prospect of inhaled biological agents in asthma
    LI Guanghui, HUANG Jing, ZHU Min, ZHAO Rui, WAN Yakun, CHEN Zhihong
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (4): 406-414.   DOI: 10.12092/j.issn.1009-2501.2024.04.007
    Abstract959)      PDF (904KB)(1026)       Save
    More than 300 million people worldwide suffer from asthma, and the incidence is increasing year by year. As one of the most common chronic diseases, asthma is an immune-mediated inflammatory disease with complex triggering mechanisms and strong heterogeneity. With the in-depth study of physiological and pathological mechanisms, therapeutic small molecule and hormone drugs have been introduced to control and treat most patients, but about 5%-10% of patients still suffer from various subtypes of difficult to control and treat asthma, that is, severe asthma. In the past decade, with the rapid development of biopharmaceutical research, protein and antibody have become the key drugs for the treatment of severe asthma with high efficacy, high specificity and high safety. However, biological drugs are usually administered by injection, they cannot be noninvasive and directly delivered into the lung to quickly absorb and take effect. Therefore, there is an urgent need for the introduction of inhaled biologics with quick effectiveness, convenience, economy and safety in clinical. The review summarizes the existing small molecule, hormone and biological therapy drugs, and summarizes the development of inhalable biological agents of asthma, and analyzes the future prospects of the inhalable biological drugs, which is designed to deepen the perception of the direction of the inhalable biological drugs research, and update the information of the field, in order to provide reference for the development of more inhalable biologics.
    Related Articles | Metrics
    Progress on anti-tumor mechanisms of Ganoderma lucidum active ingredients
    LV Yujiao, ZHOU Shuting, WANG Lina, SHEN Mingmei, LIU Yongchao
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (8): 947-954.   DOI: 10.12092/j.issn.1009-2501.2024.08.012
    Abstract952)      PDF (712KB)(2734)       Save
    Malignant tumors are one of the main causes of death from chronic diseases in China, and their incidence and mortality rates show an increasing trend year by year. Advanced non-surgical treatment of malignant tumors is an important means of improving patients' prognosis and enhancing their quality of life. The traditional Chinese medicine Ganoderma lucidum has anti-tumor effects and plays a role in the treatment of many malignant tumors. In this paper, a systematic review of the effects of Ganoderma lucidum active ingredients on tumors has been conducted at home and abroad in the past five years to explore the anti-tumor mechanism of Ganoderma lucidum active ingredients and to lay a theoretical foundation for the application of Ganoderma lucidum active ingredients in clinical practice.
    Related Articles | Metrics
    Research progress of pharmacologic therapy in obstructive sleep apnea
    WU Xingdong, YUE Hongmei, ZHU Haobin, LIU Miaomiao, LI Yating, XU Jinhui
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (2): 215-229.   DOI: 10.12092/j.issn.1009-2501.2024.02.012
    Abstract900)      PDF (1349KB)(643)       Save
    Obstructive sleep apnea (OSA) is a common sleep disordered breathing disorder. As a major global public health problem, untreated OSA can lead to a variety of adverse health outcomes, including various cardiovascular and cerebrovascular diseases, metabolic disorders, and psychiatric disorders such as anxiety and depression. Traditional OSA therapies such as positive airway pressure (PAP), weight loss, oral?appliance, upper airway surgery, and postural therapy focus on the anatomical factors of OSA. However, the pathogenesis of OSA is heterogeneous, and non-anatomical factors also play an important role in most patients. Although there is no drug with exact efficacy for the treatment of OSA, with the deepening understanding of the pathophysiological mechanism of OSA, more and more clinical studies are devoted to the study of drug treatment of OSA and its complications, and a series of results have been achieved. The following is a review of the relevant studies on drug treatment of OSA in recent years, hoping to provide literature support and theoretical basis for future research on drug treatment of OSA.
    Related Articles | Metrics
    Research progress on material basis and mechanism of Hedyotis Diffusa-Scutellaria Barbata Herb Pair in the treatment of gastric cancer
    ZHANG Xiaowei, WANG Nan, DAI Mengge, LIU Ruijuan, MA Ting
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (7): 831-840.   DOI: 10.12092/j.issn.1009-2501.2024.07.014
    Abstract855)      PDF (1074KB)(1000)       Save
    Gastric cancer is one of the most common malignant tumors in the digestive system, which often occurs in middle-aged and elderly people. Traditional Chinese medicine recognizes gastric cancer as a kind of tumor characterized by fluid deficiency, heat accumulation and the growing binding of toxins in the stomach. It is commonly treated with heat-clearing and detoxifying drugs in clinical practice. Hedyotis diffusa-Scutellaria barbata herb pair (HS) has the effects of clearing heat and detoxifying, promoting blood circulation, resolving carbuncle and expulsing boil, anti-inflammatory and analgesic, which are consistent with the etiology and pathogenesis of gastric cancer, therefore, it can be used for the treatment of gastric cancer. Modern pharmacological researches have confirmed that HS can play an anti-gastric cancer role by inducing cell apoptosis, inhibiting cell proliferation, inhibiting angiogenesis, improving immune microenvironment and down-regulating telomerase activity. Herein, this review summarizes the active ingredients and related mechanism responsible for the anti-gastric cancer effect of HS, which will provide the theoretical basis for its clinical use and the development of new drugs against gastric cancers.
    Related Articles | Metrics
    Advances in precision diagnosis and treatment of cholangiocarcinoma
    CHEN Zhenmei, CHEN Jinhong
    Chinese Journal of Clinical Pharmacology and Therapeutics    2025, 30 (2): 159-170.   DOI: 10.12092/j.issn.1009-2501.2025.02.002
    Abstract831)      PDF (909KB)(1834)       Save
    Cholangiocarcinoma (CCA) is a highly aggressive and heterogeneous biliary malignancy characterized by challenges in early diagnosis, limited efficacy of traditional chemotherapy, and poor prognosis. Due to its significant heterogeneity at the genomic, epigenetic, and molecular levels, molecular testing and targeted therapy have become increasingly important in CCA management, forming an integral part of the era of precision oncology. The development of next-generation sequencing (NGS) has advanced research into the molecular subtypes and therapeutic targets of CCA, including FGFR2 fusions/rearrangements, IDH1 mutations, and BRAF mutations. Recently, two phase III clinical trials, TOPAZ-1 and KEYNOTE-966, have established the pivotal role of immunotherapy combined with chemotherapy in advanced CCA. While precision diagnosis and treatment in CCA have shown promising progress, this field remains in its exploratory phase and faces numerous challenges. This review summarizes recent advancements in the diagnosis, molecular targeted therapy, immunotherapy, resistance mechanisms, and the development of novel strategies for CCA. 
    Related Articles | Metrics
    Current clinical application and research progress of antiplatelet drugs
    PAN Guanxing, HUANG Pinfang, CHAI Dajun, ZHANG Jing
    Chinese Journal of Clinical Pharmacology and Therapeutics    2025, 30 (1): 91-99.   DOI: 10.12092/j.issn.1009-2501.2025.01.011
    Abstract828)      PDF (934KB)(799)       Save
    Arterial thrombosis is a major cause of death in several cardiovascular diseases (CVDs), including coronary heart disease and stroke. Since platelets play a pivotal role in arterial thrombosis, antiplatelet drug is an important part of the clinical therapy of CVD patients. Currently, the long-term antithrombotic effect of the dual antiplatelet therapy of P2Y12 antagonists combined with aspirin are showed to be effective. And αΙIbβ3 antagonists represented by tirofiban are widely used for antiplatelet therapy in emergency surgery. However, the bleeding risk caused by antiplatelet therapy is a clinical issue that cannot be ignored. In order to provide a reference for further research on antiplatelet drugs, this article reviews the major targets of antiplatelet drugs and the drugs that have been under clinical research in recent years.
    Related Articles | Metrics
    Research progress of uterine endometrial epithelial cell organoids in the field of reproduction
    CAO Zhiwen, YAN Guijun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (5): 576-582.   DOI: 10.12092/j.issn.1009-2501.2024.05.013
    Abstract783)      PDF (829KB)(959)       Save
    In recent years, significant progress has been made in the study of endometrial epithelial organoids in the field of reproduction. Traditional two-dimensional cell culture models and animal experiments fail to accurately replicate the three-dimensional structure and physiological functions of the endometrium, limiting the in-depth exploration of its normal physiological mechanisms and related disease mechanisms. Emerging organoid technologies have provided new avenues for research. These organoids, formed by self-organization of stem cells or progenitor cells in a three-dimensional culture system, faithfully recapitulate the characteristics of endometrial glands in situ. Not only can these organoid models mimic the changes in the endometrium at different stages of the menstrual cycle, but they can also simulate the interaction between the fertilized embryo and the endometrium. Moreover, organoid systems have become essential tools for fundamental research in the field of reproduction and for disease research, including studies related to reproductive biology, drug screening and development, disease mechanism exploration, drug action mechanisms, drug combination therapies, and targeted therapies. These studies have provided novel insights and methods for a deeper understanding of the biological properties of the endometrium, its disease mechanisms, and the development of therapeutic strategies for related disorders.
    Related Articles | Metrics
    Current status and progress of targeted therapy for hepatocellular carcinoma
    CHEN Zhiwen, WANG Longrong, WANG Lu
    Chinese Journal of Clinical Pharmacology and Therapeutics    2025, 30 (2): 171-182.   DOI: 10.12092/j.issn.1009-2501.2025.02.003
    Abstract777)      PDF (763KB)(754)       Save
    Hepatocellular carcinoma, as a common malignant tumor, remains a serious global health problem. Traditional methods such as surgical resection and chemotherapy have limited effects in improving the prognosis of advanced hepatocellular carcinoma. With the deepening of research into molecular mechanisms, targeted therapy has become an important direction for the treatment of hepatocellular carcinoma. In this review, we summarize the main targeted drugs and associated therapeutic strategies for hepatocellular carcinoma, aiming to provide references and evidence for future related research.
    Related Articles | Metrics
    Research progress in clinical trials of new drugs and candidate drugs for type 2 diabetes mellitus
    ZHOU Xin, WANG Zhi, DU Wenyu, LIU Zihan, LI Ying, DONG Zhanjun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (10): 1185-1193.   DOI: 10.12092/j.issn.1009-2501.2024.10.012
    Abstract760)      PDF (641KB)(2021)       Save
    A number of drugs for the treatment of type 2 diabetes mellitus (T2DM) are currently under clinical investigation, including the sodium-dependent glucose transporters 2 (SGLT2) inhibitor rongliflozin, the SGLT1/2 inhibitor LIK066, the dipeptidyl peptidase-4 (DPP-4) inhibitor DBPR108, the glucagon-likepeptide-1 receptor (GLP-1R) agonist CJC-1134-PC, the G-protein-coupled receptor 40 (GRP40) agonist SCO-267 and the Glucokinase (GK) agonist PB201. This article briefly reviews the clinical research progress of drugs targeting the above targets in the field of T2DM treatment, in order to provide reference for the treatment of T2DM patients.
    Related Articles | Metrics
    Effect of Piperlongum L against pulmonary fibrosis based on network pharmacology and in vitro studies
    GUO Jingjing, ZHEN Hua, ZHANG Shengwei, JIAN Ruonan
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (10): 1120-1133.   DOI: 10.12092/j.issn.1009-2501.2024.10.005
    Abstract751)      PDF (5283KB)(615)       Save
    AIM: To predict the active components and targets of Piperlongum L. and the associated signaling pathways involved in pulmonary fibrosis using network pharmacology and molecular docking technique and evaluate the mechanism of Piperlongum L against pulmonary fibrosis by in vitro experiments. METHODS: The active ingredients and targets were retrieved from TCMSP, Swiss Target Prediction and PubChem databases. The disease-related targets were retrieved from GeneCards and OMIM databases. The intersection targets of the drugs and disease-related targets were identified using jvenn online tool. String database was used to construct the "drug-component-target" and PPI network and the networks were visualized using Cytoscape 3.9.1 software. GO and KEGG enrichment analysis were performed on the intersection targets using the DAVID tool. The top 20 KEGG pathways, core targets and drug components were used to construct a "component-target-pathway" network and the network visualization was performed using Cytoscape 3.9.1 software. The interactions between drug compounds and the targets were evaluated by molecular docking, and the docking results were visualized using Discovery studio. HFL-1 cells were cultured and the effect of the drug compounds on cell viability was determined by MTT assay. The inhibition rate was then calculated to determine the optimal drug concentration. HFL-1 cells were cultured in vitro and were assigned into 4 groups: control group, TGF-β1 group, TGF-β1+LD group (LD group), TGF-β1+HD group (HD group). CCK-8 kit was used to evaluate the antiproliferative activity of the drug compounds against HFL-1 cells at 24, 48 and 72 h. Plate clone formation assay was performed to evaluate the effect of drugs on the colony formation ability of HFL-1 cells. RT-qPCR and western blot were conducted to determine the effect of the compounds on the mRNA and protein expression levels of α-smooth muscle actin (α-SMA), collagen type I (COI-I), and collagen type III (COI-III) in each group. RESULTS: A total of 197 intersection targets of Piperlongum L and anti-pulmonary fibrosis were identified. The core PPI network comprised 29 nodes (targets) and 199 edges (interactions). GO functional analysis showed that the significantly enriched biological processes associated with the compounds in Piperlongum L included negative regulation of apoptosis, signal transduction, and protein phosphorylation. Significantly enriched cellular components included cytoplasm, nuclear cytoplasm, plasma membrane. Enriched molecular functions associated with the compounds included the same protein binding, serine/threonine/tyrosine kinase activity, and protein binding. A total of 155 significantly enriched KEGG signaling pathways were identified, with PI3K-Akt signaling pathway was highly associated with PF and was the fourth most enriched pathway. PIK3CA, MAPK3, MAPK1, MTOR, SRC, CCND1, EGFR, PRKCA, BCL2, and GSK3B had the highest connectivity in the components-target-pathway network. Piperlongine, N-(2, 5-dimethoxyphenyl) -4-methoxybenzamide, tetrahydrotanshinone, pisigenin and piperine were the key compounds in Piperlongum L. The molecular docking results showed that all the compounds except N-(2,5-dimethoxyphenyl)-4-methoxybenzamide had good binding activities with interactions observed with 10 proteins. The proliferation ability of the cells in the LD group was significantly lower than that of the TGF-β1 group at 48 h and 72 h (P<0.05). The proliferation ability of cells HD group was significantly lower than the LD group at 24, 48 and 72 h. The number of clones in each drug group was significantly reduced after treatment with the drugs (P<0.05). The mRNA and protein expression levels of α-SMA, COI-I, COI-III in LD and HD groups were significantly lower than the expression levels in the TGF-β1 group. The protein expression levels of p-PI3K/PI3K and p-Akt /AKT were significantly lower in the two dose groups compared with the TGF-β1 group (P<0.01). CONCLUSION: The results showed that the effect of Piperlongum L against PF is probably through modulation of the PI3K-Akt signaling pathway.
    Related Articles | Metrics
    Characteristics and applications in bioequivalence of physiologically based on pharmacokinetic model
    WANG Jianxiong, HU Xiao, MIAO Beibei, ZHANG Lan
    Chinese Journal of Clinical Pharmacology and Therapeutics    2025, 30 (2): 244-250.   DOI: 10.12092/j.issn.1009-2501.2025.02.012
    Abstract734)      PDF (623KB)(1114)       Save
    Physiologically based pharmacokinetics (PBPK) model is a tool to simulate the process of drug absorption, distribution, metabolism and excretion in vivo. It is widely used in drug research and regulation. In the bioequivalence evaluation of generic drug consistency evaluation and drug production process change,the PBPK model can provide a certain reference and theoretical support for the drug bioequivalence, thereby promoting safer and more economic drug clinical trials. In this paper, the application progress of PBPK model in bioequivalence study will be reviewed in order to provide support for clinical research on drugs in China.
    Related Articles | Metrics
    Targeting the cGAS-STING pathway for the treatment of ischemic stroke 
    QIAN Qingfang, LI Wenjing, LI Qiang
    Chinese Journal of Clinical Pharmacology and Therapeutics    2025, 30 (5): 690-694.   DOI: 10.12092/j.issn.1009-2501.2025.05.013
    Abstract728)      PDF (770KB)(1520)       Save
    Ischemic stroke is a devastating neurological disease worldwide, with high global burden. The microglial activation-driven neuroinflammation plays a critical role in pathophysiology of ischemic stroke. After the ictus of brain ischemic attack, cytosolic double-stranded DNA (dsDNA) released by necrotic neuronal cells is a potential damage-associated molecular pattern (DAMP) to activate cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway. cGAS-STING signaling pathway has emerged as a key player in microglial activation, sterile neuroinflammation, and cell death following ischemic stroke. Targeting this pathway holds promise for developing novel therapeutics that effectively mitigate neuroinflammation, prevent cell death, and enhance patient outcomes. In this review, we first outline the principal elements of the cGAS-STING signaling cascade, then discusses the pivotal role of the cGAS-STING pathway in ischemic stroke. Then, we outline selective small-molecules modulators that function as cGAS-STING inhibitors and summarize their mechanisms to treat Ischemic stroke. Finally, we discuss key limitations of the current therapeutic paradigm and generate possible strategies to overcome them. 
    Related Articles | Metrics
    Mechanism and treatment of mucous hypersecretion in chronic obstructive pulmonary disease
    ZHANG Ting, SUN Rong, YANG Yong, LIU Weichun, YUAN Yuping, JU Xu, WANG Qian
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (4): 383-391.   DOI: 10.12092/j.issn.1009-2501.2024.04.004
    Abstract715)      PDF (719KB)(731)       Save
    Airway mucus hypersecretion is one of the important pathophysiological and clinical manifestations of chronic obstructive pulmonary disease. It has been reported in the literature that COPD patients with chronic airway mucus hypersecretion have more frequent acute exacerbations, more severe lung function decline, and higher hospitalizations and mortality. Therefore, it is particularly critical to understand the pathogenesis of hypersecretion of mucus in chronic obstructive pulmonary disease and find out effective treatment. This article focuses on the structure, significance of airway mucus and the mechanism of hypersecretion of mucus in chronic obstructive pulmonary disease (COPD). In addition, we also summarized drug and non-drug therapy for chronic airway mucus hypersecretion in this article. Drug therapy includes traditional drug therapy, some new targeted drug therapy for pathogenesis and traditional Chinese medicine therapy, and non-drug therapy includes smoking cessation, physical therapy and bronchoscopy therapy. We hope that it will provide new ideas and directions for the treatment of mucus hypersecretion in COPD patients.
    Related Articles | Metrics
    Clinical efficacy of Tirellizumab combined with lenvatinib in the treatment of advanced liver cancer
    WU Yuanyuan, LI Chenlu, CHEN Yan, CAO Mengda, SHAO Hua
    Chinese Journal of Clinical Pharmacology and Therapeutics    2025, 30 (3): 392-397.   DOI: 10.12092/j.issn.1009-2501.2025.03.012
    Abstract703)      PDF (642KB)(410)       Save
    AIM: To investigate the efficacy and safety of checkpoint inhibitor lenvatinib combined with Tirelizumab in the treatment of advanced hepatocellular carcinoma (HCC). METHODS: A retrospective analysis was performed on 52 patients with advanced HCC treated with Renvatinib, tirellizumab or their combination from January 2021 to December 2022 in Zhongda Hospital Affiliated to Southeast University, with disease progression, death and intolerance as endpoints. Efficacy was assessed according to RECIST 1.1 criteria and follow-up was conducted up to June 2023. The main endpoints of the study were objective response rate (ORR), disease control rate (DCR), progression-free survival, PFS) and security. RESULTS: The combination therapy significantly improved ORR and mPFS in patients compared with tirelizumab or lenvatinib monotherapy. Compared with single tirellizumab or lenvastinib, there was no significant difference in the adverse reactions associated with the combination treatment, suggesting that the combination of the two was generally well tolerated and the side effects are controllable. CONCLUSION: Lonvastinib combined with tirelizumab is more effective in the treatment of HCC, can significantly prolong PFS, and is generally well tolerated, which may be a potential treatment for advanced HCC.
    Related Articles | Metrics
    Analysis of hyperglycaemia adverse drug reactions of PCSK9 inhibitors and statins based on FAERS database
    Analysis of hyperglycaemia adverse drug reactions of PCSK inhibitors and statins based on FAERS database
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (7): 762-767.   DOI: 10.12092/j.issn.1009-2501.2024.07.005
    Abstract691)      PDF (554KB)(277)       Save
    AIM: To compare the risk of hyperglycaemia with PCSK9 inhibitors versus statins, based on U.S. Food and Drug Administration Adverse Events Reporting System (FAERS). METHODS: The hyperglycaemia reports induced by "alirocumab", "evolocumab", "atorvastatin" and "rosuvastatin" were utilized as the first suspected drugs from the database of FAERS from 2016 to the third quarter of 2023. The report odd ratio (ROR) method was employed. RESULTS: Based on the FAERS database, the ROR (95% CI) for hyperglycaemia due to Alirocumab versus Atorvastatin and Rosuvastatin were 0.628(0.545, 0.724) and 0.307 (0.263, 0.357) , the ROR (95% CI) for hyperglycaemia due to Evolocumab were 0.817 (0.750, 0.889) and 0.399 (0.361, 0.441) , all generated no adverse reaction signals. The ROR (95% CI) for hyperglycaemia due to Alirocumab and Evolocumab versus all other drugs in FAERS were 1.488(1.315,1.682) and 1.934(1.845, 2.027), all generated adverse reaction signals, respectively. CONCLUSION: Based on the FAERS database, PCSK9 inhibitors have a lower risk of hyperglycemia than statins and deserve clinical attention.
    Related Articles | Metrics
    Application of single-cell multi-omics sequencing technology in the study of ischemic stroke
    MENG Qian, WANG Yiwen, CUI Na, BAI Min, YANG Le, DING Yi
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (6): 690-699.   DOI: 10.12092/j.issn.1009-2501.2024.06.011
    Abstract691)      PDF (810KB)(1358)       Save
    Ischemic stroke is an acute cerebrovascular disease with high disability and mortality, is the most common cause of death in China. Despite years of research, there are still no biomarkers for stroke, and the molecular mechanisms remain largely unknown. In the past decade, single-cell sequencing technology, as a rapidly developing emerging technology, can conduct high-throughput sequencing of multiple omics including genome, transcriptome, epigenome and proteome at the level of a single cell, providing a new way to discover biomarkers and analyze pathological mechanisms. In this paper, the progress of single-cell multi-omics sequencing technology and its application in the discovery of biomarkers, pathological mechanisms and drug development of ischemic stroke are introduced in detail, in order to provide valuable reference for precision medicine of ischemic stroke.
    Related Articles | Metrics
    Rapid health technology assessment of dienogest in the treatment of endometriosis
    GUO Hua, LIU Lanlan, HUANG Chunzhi, SUN Nan, REN Yanli
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (5): 512-519.   DOI: 10.12092/j.issn.1009-2501.2024.05.005
    Abstract682)      PDF (616KB)(406)       Save
    AIM: To rapidly evaluate the effectiveness, safety and economy of dienogest in the treatment of endometriosis so as to provide evidence-based reference for clinical drug selection and decision. METHODS: Retrieved from PubMed, Embase, Cochrane Library, CNKI, SinoMed, Wanfang and health technology assessment (HTA) organization websites, HTA report, systematic review/Meta-analysis and pharmacoeconomic study were included during the inception to Sep 2023. Data extraction and quality evaluation were carried out for the literature that met the inclusion and exclusion criteria, and the research results were summarized and analyzed qualitatively. RESULTS: Nine systematic review/Meta-analyses, and 2 pharmacoeconomic studies were included. The quality of Meta-analysis literatures was low, and the quality of economic research was good. In terms of effectiveness, compared with no treatment, dienogest can significantly reduce postoperative recurrence rate, VAS score, and improve pregnancy rate and effective rate; Dienogest has similar therapeutic effects in terms of recurrence rate as GnRHa and COC; With regard to recurrence rate and pregnancy rate, dienogest is superior to danazol, gestrinone, and mifepristone. In terms of safety, compared with placebo, the incidence of vaginal bleeding and headache was significantly increased with dienogest, and there was no difference in bone loss; The incidence of vaginal bleeding caused by dienogest was significantly higher than that of GnRHa, but the incidence of hot flashes and bone loss was lower. In terms of economy, dienogest has a more cost-effective advantage comparing with GnRHa, but does not have economic benefits comparing with COC. CONCLUSION: Dienogest has good effectiveness and safety in the treatment of endometriosis, and economically superior to GnRHa, but inferior to COC.
    Related Articles | Metrics
    Effects of remimazolam on early postoperative cognitive function in elderly patients with hip fracture
    DUAN Gongchen, WU Jimin, XU Qiaomin, JIANG Jianxin, LAN Haiyan, ZHANG Xutong, YUAN Kaiming, LI Jun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (2): 146-153.   DOI: 10.12092/j.issn.1009-2501.2024.02.004
    Abstract673)      PDF (749KB)(664)       Save
    AIM: To evaluate the effect of remimazolam on early postoperative cognitive function in elderly patients with hip fracture based on a randomized controlled trial. METHODS: A total of 106 elderly patients, aged 65-90 years, ASA grade Ⅱ or Ⅲ, who underwent hip fracture surgery under combined spinal-epidural anesthesia in the Sixth Affiliated Hospital of Wenzhou Medical University from December 2022 to June 2023 and met the inclusion criteria, were selected and randomized into remimazolam group (group R) and propofol group (group P) according to the random number table, with 53 cases in each group. Patients in group P received a slow intravenous injection of propofol at a dose of 0.3-0.5 mg/kg (injection time of 1min), followed by a pump infusion at 0.5-3 mg·kg-1·h-1 for maintenance. In group R, intraoperative sedation was maintained by remimazolam at 0.1-0.3 mg·kg-1·h-1 after a loading dose of 0.05 mg/kg (injection time of 1min). The pump infusion rate were adjusted by maintaining MOAA/S score at 3-4 and BIS value at 75-85, and stopped administering sedatives while suturing the incision. MOAA/S score, MAP, HR, RR, SpO2 and BIS values were recorded before sedation (T0), 5 (T1), 10 (T2), 15 (T3), 30 (T4) and 60 (T5) min after sedation and at the end of surgery. The emergence time, intraoperative amnesia, the incidence of postoperative delirium (POD) and delayed neurocognitive recovery (DNR) within 7 days after operation, and the occurrence of adverse events during perioperative observation were recorded. RESULTS: Compared with T0, the BIS and MOAA/S scores of the two groups at T1-T5 were significantly decreased, and the MAP and HR of the two groups at T1-T6 were significantly lower (P<0.05). Compared with group P, group R showed higher MAP at all time points from T1 to T6 (all P<0.05), shorter emergence time (6.6±1.8 vs. 7.7±2.2 min, P<0.05), less decline in Hopkins Verbal Learning Test scores on postoperative day 7 (3.9±3.9 vs. 6.2±4.6, P<0.05), lower incidence of postoperative delirium and DNR (7.5% vs. 28.3%,5.7% vs. 20.8%, P<0.05), higher incidence of intraoperative amnesia (52.8% vs. 28.3%, P<0.05) lower incidence of hypotension and bradycardia (15.1% vs. 37.7%, 5.6% vs. 22.6%, P<0.05), and fewer frequent use of vasoactive drugs (P<0.05). CONCLUSION: Application of remimazolam for perioperative sedation in elderly patients with hip fracture can provide effective sedation and stable hemodynamic, with little effect on early neurocognitive function, and overall safety higher than propofol.
    Related Articles | Metrics
    Recent progress of targeting Nrf2-ferroptosis to treat brain injury after ischemic stroke
    LI Mei, LI Qiang
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (2): 188-197.   DOI: 10.12092/j.issn.1009-2501.2024.02.009
    Abstract657)      PDF (973KB)(621)       Save
    Emerging evidences suggest that ferroptosis plays a vital role in the pathophysiological process of brain injury after Ischemic stroke. Accumulating evidence supports  pharmacological inhibition of ferroptosis as a therapeutic target for brain injury after Ischemic stroke through activating nuclear factor erythroid 2-related factor 2 (Nrf2), which transcriptionally controls many key components of the ferroptosis pathway. In this review, briefly describe ferroptosis processes and the roles they play in contributing to brain injury after ischemic stroke in the brain. We then provide a critical overview of the relationship between Nrf2 signalling and ferroptosis. With a focus on discuss how therapeutic modulation of the Nrf2 pathway is a viable strategy to explore in the treatment of ferroptosis-driven brain injury after Ischemic stroke.
    Related Articles | Metrics
    The mechanism and application prospects of mitochondrial quality control in osteoarthritis
    WANG Liang, DENG Yinshuan, QU Tao, DA Chaoming, HE Yunfei, LIU Rui, NIU Weimin, YAN Weishun, CHEN Zhen, LI Shuo, YANG Zhiyun, GUO Binbin, LAI Xueqian
    Chinese Journal of Clinical Pharmacology and Therapeutics    2025, 30 (2): 282-288.   DOI: 10.12092/j.issn.1009-2501.2025.02.016
    Abstract646)      PDF (615KB)(1229)       Save
    Osteoarthritis (OA) is a common joint disease in clinical practice, and cartilage damage is a typical pathological change. The pathogenesis of OA is complex, and various adverse factors can lead to the occurrence of OA. Mitochondria are important organelles within cells and play important roles in cellular physiological and pathological activities. Mitochondrial quality control is an important regulatory mechanism in the body to maintain normal mitochondrial structure and function, mainly including mitochondrial biogenesis, mitochondrial dynamics, mitochondrial autophagy, mitochondrial oxidative stress, and other forms. The imbalance of mitochondrial quality control in chondrocytes is closely related to the occurrence and development of osteoarthritis, and regulating the balance of mitochondrial quality control is a potential therapeutic point for osteoarthritis. The author reviewed relevant research literature in recent years to provide a review of the relationship between mitochondrial quality control and the occurrence and development of osteoarthritis, in order to provide new ideas and directions for the research and diagnosis and treatment strategies of osteoarthritis.
    Related Articles | Metrics
    Research progress on the addictivity and neurotoxicity of ketamine
    ZI Zhian, ZHAO Tingyi, WANG Gongwu, CAO Jun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2025, 30 (9): 1233-1242.   DOI: 10.12092/j.issn.1009-2501.2025.09.010
    Abstract639)      PDF (676KB)(560)       Save
    As a new type of rapid antidepressant, ketamine has provided a new approach for the treatment and research on the pathological mechanism of major depressive disorder. However, the addictive potential and neurotoxicity of ketamine have become issues that cannot be ignored in clinical medication. This article briefly introduces the relevant research progress on ketamine addiction and neurotoxicity mechanisms at home and abroad, hoping to provide a reference for the rational development and utilization of ketamine.
    Related Articles | Metrics
    Low-dose rituximab improves progression in early-stage medium-to-high-risk membranous nephropathy: an exploratory study
    XU Qiuyu, AI Sanxi, WANG Gangan, JIA Chunyu, WANG Jiahui, ZHENG Ke, QIN Yan, CHEN Gang, LI Xuemei
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (7): 744-751.   DOI: 10.12092/j.issn.1009-2501.2024.07.003
    Abstract635)      PDF (1117KB)(1187)       Save
    Membranous nephropathy (MN) is the predominant cause of primary nephrotic syndrome (NS) among adults. The identification of PLA2R as target antigen has brought about a profound transformation in the management of MN, offering a basis for the utilization of B-cell depleting agents such as rituximab (RTX). The question of whether early intervention targeting antibodies can effectively impede the progression of MN, contributing to enhanced disease control and long-term renal outcomes for patients, remains further exploration. We analyzed demographic data, laboratory parameters, and renal involvement in 13 patients with PLA2R antibody-related MN who received at least one RTX treatment at our center from October 2019 to March 2023. Early-stage medium-to-high-risk MN was defined as baseline or admission anti-PLA2R antibody levels exceeding 50 RU/mL, excluding patients who already presented with nephrotic syndrome at baseline. The median duration of MN at the initiation of the first RTX treatment was 4.1 months (IQR 1-7.7), and the median follow-up time after RTX therapy was 27 months (IQR 23-45). All patients had commenced renin-angiotensin system inhibitors before receiving RTX. Following RTX therapy, none of the 13 patients progressed to NS during the follow-up period, and 12 patients achieved complete or partial remission at the 2-year follow-up or the last visit. No deaths, severe infections, or other serious adverse reactions occurred during the follow-up period. In conclusion, RTX demonstrates favorable efficacy and safety in early-stage, medium-to-high-risk MN patients. Initiating antibody clearance therapy in these patients may be beneficial for long-term disease control and distant renal outcomes.
    Related Articles | Metrics
    SAS macro tool for pharmacokinetic parameter estimation based on non-compartmental models
    ZHANG Li, LOU Donghua
    Chinese Journal of Clinical Pharmacology and Therapeutics    2025, 30 (5): 608-621.   DOI: 10.12092/j.issn.1009-2501.2025.05.004
    Abstract623)      PDF (706KB)(687)       Save
    AIM: To develop a SAS macro tool for calculating pharmacokinetic (PK) parameters using non-compartmental analysis (NCA) that is applicable to various routes and frequencies of drug administration. METHODS: By incorporating the principles of NCA PK parameter calculations, the structure of the SAS macro program is designed and programmed. The usage of the macro program is demonstrated through simulated examples. RESULTS: Based on NCA, this study programmed a SAS macro using SAS macro language to calculate both single-dose and steady-state complete PK parameters. It supports three modes of drug administration: extravascular, intravenous infusion, and intravenous bolus injection, as well as four algorithms for calculating area under the curve (AUC). By comparing with authoritative calculation software, the results were found to be highly consistent across various calculation scenarios, with more accurate calculations for the time of first measurable concentration (Tlag). CONCLUSION: The %M_CREATE_PK_PARAMETERS macro is a SAS macro that supports comprehensive PK parameter calculations in NCA, providing an accurate, efficient, and flexible solution for PK parameter estimation with broad application prospects.
    Related Articles | Metrics
    Novel mechanisms driving renal tubulointerstitial fibrosis
    ZHANG Yanni, DUAN Yuxin, BAI Yi, YU Jinyao, SUN Jiayi, WANG Zejie, LI Ling, YE Qifa
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (3): 348-353.   DOI: 10.12092/j.issn.1009-2501.2024.03.014
    Abstract620)      PDF (1252KB)(848)       Save
    Renal fibrosis, especially tubulointerstitial fibrosis, is the most common pathway of all chronic kidney diseases progressing to end-stage renal diseases. Several adaptive reactions occur in renal tubular epithelial cells after chronic injury, such as changes in glycolipid metabolism, unfolded protein response, autophagy and senescence, epithelial-to-mesenchymal transition and G2/M cell cycle arrest. Maladaptive repair mechanisms can induce tubulointerstitial fibrosis. This article will discuss the molecular mechanism of these adaptive responses of renal tubular epithelial cells driving renal tubulointerstitial fibrosis, and provide a basis for exploring new drug targets for renal tubulointerstitial fibrosis.
    Related Articles | Metrics
    Targeted biotherapy for chronic obstructive pulmonary disease
    BAI Haodong, SHA Bingxian, Ambedkar Kumar Yadav, XU Xianghuai, YU Li
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (4): 377-382.   DOI: 10.12092/j.issn.1009-2501.2024.04.003
    Abstract605)      PDF (640KB)(486)       Save
    Chronic obstructive pulmonary disease (COPD) is the most common chronic airway disease. The current status of treatment based mainly on bronchodilators and ICS is not sufficient for all of COPD patients. Various studies have attempted to use biologics targeting specific cytokines and their receptors in COPD patients to alleviate respiratory symptoms or reduce the risk of acute exacerbations. However, they failed to bring significant clinical benefits. More studies are needed to further determine the efficacy of targeted biotherapy for COPD.
    Related Articles | Metrics
    Effects of low concentration atropine on macular microcirculation in children with different degrees of myopia
    GE Wei, SHENG Wenyan, XU Qibin, ZHU Liwei, LI Qiushi
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (3): 303-309.   DOI: 10.12092/j.issn.1009-2501.2024.03.009
    Abstract599)      PDF (628KB)(440)       Save
    AIM: To investigate the effects of 0.01% atropine eye drops on macular blood flow density and retinal thickness in children with different degrees of myopia. METHODS: This was a prospective case-control study. Sixty-four patients (112 eyes) diagnosed with myopia for the first time with 0.01% atropine eye drops before and 6 months after medication were investigated with the uncorrected distance visual acuity (UCVA), axial length (AL), spherical equivalent (SE), macular ganglion cell-inner plexiform layer thicknes (mGCIPL) using slit lamp examination and optical coherence tomography (OCT), vascular density in the macular area and the area of the avascular in the fovea using optical coherence tomography angiography (OCTA) . Changes in various indicators before and after medication were compared. RESULTS: Compared with before medication, the AL of the three groups of myopia patients increased significantly (P<0.01), the difference in low to moderate myopia group was significantly smaller than that in high myopia group.Compared with before medication, SE increased in all three groups of myopia patients, yet there was no statistically significant difference in the low-grade myopia group (P>0.05). The difference was statistically significant between the moderate myopia group and the high myopia group (P<0.01). Compared with before medication, there was no change in intraocular?pressure (IOP) among the three groups of myopic patients (P>0.05). After 6 months of medication, the central circle macular vessel density (cCVD) increased in the low myopia group and moderate myopia group (P<0.01), there was no statistically significant difference in the high myopia group (P>0.05). Before and after medication, there was no significant difference in outer circle macular vessel density (oCVD), inner circle macular vessel density (iCVD), and whole circle macular vessel density (wCVD) among the three myopia groups (P>0.05). The increase in mGCIPL was statistically significant in the low myopia group (P<0.01), but there was no statistically significant difference in the moderate myopia and high myopia groups (P>0.05).There was no significant difference in foveal avascular zone (FAZ) among the three myopia groups before and after medication (P>0.05). There was no correlation between CVD, AL, and SE in the three myopia groups (P>0.01).There was a low correlation between CVD and mGCIPL in the low myopia group (r=0.442, P<0.05), there was no correlation between CVD and mGCIPL in the moderate myopia and high myopia groups (P>0.01). CONCLUSION: 0.01% atropine can significantly reduce the rate of axial and refractive growth in children with low to moderate myopia, increase the density of central macular vessels, and increase the thickness of mGCIPL in children with low to moderate myopia.
    Related Articles | Metrics
    Progress in perioperative application of tranexamic acid
    WANG Wenli, YAO Yiting, YANG Chun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (2): 198-206.   DOI: 10.12092/j.issn.1009-2501.2024.02.010
    Abstract585)      PDF (649KB)(886)       Save
    Perioperative bleeding is closely related to the prognosis of patients, and massive blood loss can lead to serious adverse events. Tranexamic acid, a lysine derivative, exerts anti-fibrinolytic effects by competitively blocking lysine binding sites on plasminogen to achieve hemostasis. Perioperative use of tranexamic acid can effectively reduce the risk of bleeding and the need for blood transfusion, and reduce the risk of bleeding related complications and death. At present, the use of tranexamic acid for perioperative hemostasis is increasingly widespread, and it is gradually entering the consensus and guidelines in more surgical fields. In this paper, the mechanism of action, perioperative application and adverse reactions of tranexamic acid were reviewed, and the effectiveness and safety of tranexamic acid in different surgical types were discussed, so as to provide reference for the application and research of tranexamic acid in China.
    Related Articles | Metrics
    Research progress of epigenetics in the pathogenesis of depression
    ZHANG Yao, ZOU Manshu, HAN Yuanshan, WANG Yuhong
    Chinese Journal of Clinical Pharmacology and Therapeutics    2025, 30 (4): 517-525.   DOI: 10.12092/j.issn.1009-2501.2025.04.010
    Abstract585)      PDF (924KB)(1263)       Save
    Depression is a mental disease with increasing prevalence worldwide, which seriously endangers human health with high disability rate and high suicide rate. Epigenetics is an emerging genetic theory in the 21st century. Its main research content is to regulate the process of gene transcription or translation and affect its function and characteristics without changing the DNA sequence. These include DNA methylation, histone modification, chromatin remodeling and non-coding RNA regulation. The nervous system is susceptible to changes in the activity of epigenetic modifiers, and an increasing number of studies have shown that genetics and environment play an important role in the development of depression. This review will focus on the epigenetic mechanisms of depression.
    Related Articles | Metrics
    Signal mining and analysis of adverse drug reactions for polatuzumab vedotin based on FAERS database
    SONG Zaiwei, LI Xinya, MEN Peng, JIANG Dan, DONG Fei, ZHAO Rongsheng, YANG Jun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (7): 752-761.   DOI: 10.12092/j.issn.1009-2501.2024.07.004
    Abstract584)      PDF (709KB)(1015)       Save
    AIM: To evaluate and analyze the post-marketing adverse drug reaction (ADR) signals of polatuzumab vedotin, so as to provide reference for clinical safety management. METHODS: Using the FDA adverse drug event reporting system (FAERS) database and OpenVigil data platform, the ADR reports of polatuzumab vedotin were collected from June 10, 2019 (FDA approval for marketing) to the March 31, 2023. The ADR signals were detected by using the reporting odds ratio (ROR) and proportional reporting ratio (PRR) in the proportional imbalance method. To increase the threshold and obtain stronger and more frequently occurring ADRs, a second screening of signals was performed. RESULTS: A total of 2 408 ADR reports related to polatuzumab vedotin were collected, and 83 ADR signals were detected after secondary screening. 26 ADR signals were not mentioned in the drug instructions such as abnormal spinal magnetic resonance imaging, increased bone resorption, osteolysis, decreased aspartate aminotransferase, decreased alanine aminotransferase, hypofibrinogenemia, and pulmonary embolism. The system organ classes with a high signal counts or cumulative number of cases included infections and invasive diseases (24 signals, 632 cases), various examinations (17 signals, 675 cases), blood and lymphatic system diseases (11 signals, 734 cases), various nervous system diseases (7 signals, 153 cases), immune system diseases (3 signals, 95 cases), systemic diseases and various reactions at the site of administration (2 signals, 145 cases), and systemic diseases and various reactions at the site of administration (2 signals, 87 cases), etc. CONCLUSION: In addition to the common ADRs suggested by the instructions, this study identified new ADR risk signals for polatuzumab vedotin. In the clinical application of polatuzumab vedotin, in addition to the ADR mentioned in the instructions such as infections, myelosuppression, peripheral neuropathies, infusion-related reactions, and abnormal liver function, attention should also be paid to the risk signals not mentioned such as abnormal spinal magnetic resonance imaging, and increased bone resorption.
    Related Articles | Metrics
    Icariin improves hypertensive renal fibrosis and injury through Cx32-Nox4 signaling pathway
    WU Xiaoxue, YE Yiping, LEI Zhendong, ZHANG Zunjing, CHEN Wenling
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (8): 870-878.   DOI: 10.12092/j.issn.1009-2501.2024.08.004
    Abstract584)      PDF (1794KB)(196)       Save
    AIM: To investigate the effect of icariin on renal fibrosis and injury in hypertension through Cx32-Nox4 signaling pathway. METHODS: Models of hypertensive nephropathy (HN) were established in spontaneously hypertensive rats (SHRs). The experiment was divided into 4 groups: normal control group (WKY rats), model group (SHR), icariin 10 mg·kg-1·d-1 group (icariin once daily), icariin 30 mg·kg-1·d-1 group (icariin once daily), n=10. The expression of fibrosis-related proteins was detected in vivo. NRK-52E cells exposed to AngII were selected to observe the effects of icariin on kidney injury. Extracellular matrix (ECM) levels, including α-smooth muscle actin (α-SMA), collagen I (Col-I) and fibronectin (FN) expression were measured by Western blot and immunohistochemistry. The expressions of oxidative stress markers including superoxide dismutase (SOD) and malondialdehyde (MDA) were determined by the test kit. RESULTS: Icariin reduced renal fibrosis in SHR rats in vivo. Icariin down-regulated the expression of α-SMA, FN, and Col-I and protected hypertension-damaged kidney tissue from progressive fibrosis (P<0.05). Icariin increased the total SOD activity and decrease the MDA level in kidney and serum of SHR rats (P<0.05). In addition, icariin increased the expression of Cx32 and decreased the expression of Nox4 in the kidneys of SHR rats (P<0.05). Icariin had a protective effect on AngII-mediated NRK-52E cell damage and fibrosis. CONCLUSION: Icariin can improve renal tubulointerstitial fibrosis and delay the progression of HN. Renal protection may be attributed to the regulation of oxidative stress mediated by the Cx32-Nox4 signaling pathway.
    Related Articles | Metrics
    Research progresses of nonsense-mediated mRNA decay in tumorigenesis and cancer therapy
    WANG Yuhui, WANG Jingpeng, CHEN Bei, WANG Yaru, LI Tangliang
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (8): 930-936.   DOI: 10.12092/j.issn.1009-2501.2024.08.010
    Abstract582)      PDF (815KB)(523)       Save
    Nonsense-mediated mRNA decay (NMD) is a highly conserved post-transcriptional regulatory mechanism in eukaryotic cells. NMD can recognize and degrade abnormal transcripts containing premature termination codons (PTC) to prevent the translation of C-terminal truncated proteins. Furthermore, NMD could degrade a subset of normal gene transcripts and thus fine-tune gene expression. NMD is essential for cell fate determination, stress response, as well as animal development. In this review, we briefly discussed the functional and molecular mechanisms of NMD pathway activation and inhibition in tumorigenesis, cancer progression and therapy. Current studies indicate that NMD factor mutations can lead to a variety of human tumors. Interestingly, inhibition of NMD factors can activate DNA damage response and inhibit the expression of oncogenic factors, thereby killing cancer cells. This review may provide new perspectives for the biological mechanism and therapeutic strategy of human tumors.
    Related Articles | Metrics